“…However, as the hypotheses concerning particular disorders vary, so do the stimulation targets: OCD (7 targets tested), MDD (7), Tourette's (6), anorexia nervosa (4), addiction (3), anxiety (2), obesity (2) and post‐traumatic stress disorder (PTSD) (1) (Lee et al., 2019). To date, DBS treatment has been approved only for OCD (receiving a Humanitarian Device Exemption from the Food and Drug Administration (FDA) in 2008 to target the anterior limb of the internal capsule); stimulation in other psychiatric disorders, including Depression, fall under the “investigational” trial category (for summary of results, see Cleary et al., 2015; Cormier et al., 2019; Graat et al., 2017; Lee et al., 2019).…”